OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
Heather J. Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 5, pp. 1391-1398
Open Access | Times Cited: 32
Heather J. Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 5, pp. 1391-1398
Open Access | Times Cited: 32
Showing 1-25 of 32 citing articles:
Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance
Thais Pereira‐Veiga, Svenja Schneegans, Klaus Pantel, et al.
Cell Reports (2022) Vol. 40, Iss. 9, pp. 111298-111298
Open Access | Times Cited: 103
Thais Pereira‐Veiga, Svenja Schneegans, Klaus Pantel, et al.
Cell Reports (2022) Vol. 40, Iss. 9, pp. 111298-111298
Open Access | Times Cited: 103
Liquid biopsy for human cancer: cancer screening, monitoring, and treatment
Hao Wang, Yi Zhang, Hao Zhang, et al.
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 21
Hao Wang, Yi Zhang, Hao Zhang, et al.
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 21
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach
Dhivya Sridaran, Elliot Bradshaw, Carl J. DeSelm, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101199-101199
Open Access | Times Cited: 27
Dhivya Sridaran, Elliot Bradshaw, Carl J. DeSelm, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101199-101199
Open Access | Times Cited: 27
New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication
Sha Qin, Bin Xie, Qingyi Wang, et al.
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 13
Sha Qin, Bin Xie, Qingyi Wang, et al.
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 13
Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer
Cheng Zhang, Xiaoyi Chong, Fangli Jiang, et al.
Journal of Extracellular Vesicles (2022) Vol. 11, Iss. 4
Open Access | Times Cited: 35
Cheng Zhang, Xiaoyi Chong, Fangli Jiang, et al.
Journal of Extracellular Vesicles (2022) Vol. 11, Iss. 4
Open Access | Times Cited: 35
Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
Ruixia Song, Fengsen Liu, Yu Ping, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Ruixia Song, Fengsen Liu, Yu Ping, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy
Joyce K. Hwang, Eda K. Holl, Yuan Wu, et al.
JCI Insight (2025)
Open Access
Joyce K. Hwang, Eda K. Holl, Yuan Wu, et al.
JCI Insight (2025)
Open Access
Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy
Rosalyn M. Fey, Avery Billo, Terri Clister, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 732-732
Open Access
Rosalyn M. Fey, Avery Billo, Terri Clister, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 732-732
Open Access
Cellular Immunity in Patients With Small Cell Lung Cancer in Presence and Absence of Circulating Tumor Cells
M. A. Khomidov, E. Yu. Zlatnik, Inna A. Novikova, et al.
Innovative medicine of Kuban (2025) Vol. 10, Iss. 1, pp. 56-62
Open Access
M. A. Khomidov, E. Yu. Zlatnik, Inna A. Novikova, et al.
Innovative medicine of Kuban (2025) Vol. 10, Iss. 1, pp. 56-62
Open Access
Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors
Jiayu Diao, Zhigong Wei, Yiyan Pei, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Jiayu Diao, Zhigong Wei, Yiyan Pei, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Antimetastatic defense by CD8+ T cells
Paulino Tallón de Lara, Héctor Castañón, Michelle Sterpi, et al.
Trends in cancer (2021) Vol. 8, Iss. 2, pp. 145-157
Open Access | Times Cited: 23
Paulino Tallón de Lara, Héctor Castañón, Michelle Sterpi, et al.
Trends in cancer (2021) Vol. 8, Iss. 2, pp. 145-157
Open Access | Times Cited: 23
Liquid biopsy for cancer immunotherapy: Biomarkers to predict and monitor response upon immune checkpoint blockade
Chae Yeon Son, Deborah Lee, Hyun Sung Park, et al.
Coordination Chemistry Reviews (2025) Vol. 539, pp. 216767-216767
Closed Access
Chae Yeon Son, Deborah Lee, Hyun Sung Park, et al.
Coordination Chemistry Reviews (2025) Vol. 539, pp. 216767-216767
Closed Access
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
Αreti Strati, Panagiota Economopoulou, Evi Lianidou, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1768-1768
Open Access | Times Cited: 8
Αreti Strati, Panagiota Economopoulou, Evi Lianidou, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1768-1768
Open Access | Times Cited: 8
Prognostic significance of programmed cell death‐ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta‐analysis
Yu-Shu Ouyang, Wendao Liu, Ningning Zhang, et al.
Cancer Medicine (2021) Vol. 10, Iss. 20, pp. 7021-7039
Open Access | Times Cited: 18
Yu-Shu Ouyang, Wendao Liu, Ningning Zhang, et al.
Cancer Medicine (2021) Vol. 10, Iss. 20, pp. 7021-7039
Open Access | Times Cited: 18
An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets
Eunice Dotse, King Hoo Lim, Meijun Wang, et al.
Life (2022) Vol. 12, Iss. 2, pp. 323-323
Open Access | Times Cited: 12
Eunice Dotse, King Hoo Lim, Meijun Wang, et al.
Life (2022) Vol. 12, Iss. 2, pp. 323-323
Open Access | Times Cited: 12
The effect of ginsenoside Rg3 combined with chemotherapy on immune function in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
Song Gao, Cancan Fang, Tiancheng Wang, et al.
Medicine (2023) Vol. 102, Iss. 14, pp. e33463-e33463
Open Access | Times Cited: 7
Song Gao, Cancan Fang, Tiancheng Wang, et al.
Medicine (2023) Vol. 102, Iss. 14, pp. e33463-e33463
Open Access | Times Cited: 7
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Ao Huang, Xin Zhang, Jian Zhou
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Ao Huang, Xin Zhang, Jian Zhou
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 16
CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC
Mizanur Rahman, Muhammad Mosaraf Hossain, S. M. Didar-Ul Islam, et al.
BMC Molecular and Cell Biology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Mizanur Rahman, Muhammad Mosaraf Hossain, S. M. Didar-Ul Islam, et al.
BMC Molecular and Cell Biology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy
Junlei Hou, Xuezhi Yang, Shuanglong Xie, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Junlei Hou, Xuezhi Yang, Shuanglong Xie, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Peripheral blood–derived PD-1/CD28–CD19-CAR–modified PD-1+ T-cell therapy in patients with solid tumors
Zhen Zhang, Xuan Zhao, Qitai Zhao, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 12, pp. 1703-1717
Closed Access | Times Cited: 2
Zhen Zhang, Xuan Zhao, Qitai Zhao, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 12, pp. 1703-1717
Closed Access | Times Cited: 2
The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype
Jingjing Yu, Chang Shu, Huiyuan Yang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 13
Jingjing Yu, Chang Shu, Huiyuan Yang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 13
Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis
Milena Shizue Tariki, Caroline Correia Ghensev Barberan, Jacqueline Aparecida Torres, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 154918-154918
Closed Access | Times Cited: 4
Milena Shizue Tariki, Caroline Correia Ghensev Barberan, Jacqueline Aparecida Torres, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 154918-154918
Closed Access | Times Cited: 4
Characteristics and postoperative dynamic changes in circulating CD4+ helper T lymphocytes in patients with breast cancer
Yan Lu, Qiaohong Zhang, Jiang Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Yan Lu, Qiaohong Zhang, Jiang Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
Αreti Strati, Panagiota Economopoulou, Evi Lianidou, et al.
(2023)
Open Access | Times Cited: 3
Αreti Strati, Panagiota Economopoulou, Evi Lianidou, et al.
(2023)
Open Access | Times Cited: 3
Organ preservation in muscle-invasive urothelial bladder cancer
Scot A. Niglio, Juhi M. Purswani, Peter B. Schiff, et al.
Current Opinion in Oncology (2024) Vol. 36, Iss. 3, pp. 155-163
Closed Access
Scot A. Niglio, Juhi M. Purswani, Peter B. Schiff, et al.
Current Opinion in Oncology (2024) Vol. 36, Iss. 3, pp. 155-163
Closed Access
